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Patients with stoma evaluated their life quality only with 42.33 points from the 
overall 80. ConClusions: Patients with intestinal diseases are defatigable, and 
have abdominal problems frequently. In case of ulcerative colitis the burden of 
disease is higher, life quality is less favourable. Stoma negatively affects life qual-
ity. The residence is significantly affected by the disease burden and quality of life.
PGI51
The DemoGraPhIc asPecTs of TurkIsh chronIc hePaTITIs c PaTIenTs 
anD The TreaTmenT InITIaTIon from a PhysIcIan’s & PaTIenT’s PoInT 
of VIew. fIrsT InTerIm analysIs of TurkIsh DaTa from mosaIc sTuDy 
(an InTernaTIonal mulTIcenTer ProsPecTIVe obserVaTIonal sTuDy 
To eValuaTe The ePIDemIoloGy, humanIsTIc anD economIc ouTcomes 
ofTreaTmenT for chronIc hePaTITIs c VIrus)
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objeCtives: Chronic Hepatitis C Virus (HCV) infection negatively impacts the 
patient’s quality of life. Interferon (IFN) based therapy has been the standard of 
care for many years yet antiviral therapy of HCV has rapidly evolved since the 
introduction of direct acting antivirals (DAA). This report is based on Turkish Mosaic 
Study. The objective is to characterize patients with chronic HCV and assess the 
impact of IFN-containing treatment on health related quality of life, work related 
productivity and activities of daily living and health care utilization. Methods: 
MOSAIC is an international prospective multicenter observational study that is 
conducted in 20 countries. Consecutive patients with chronic HCV who initiated an 
IFN based treatment within 12 weeks were followed for 48 weeks. Patient charac-
teristics, co-morbidities, treatment history, HCV genotype and clinical status were 
recorded. The response type recorded for previous treatment as null response, 
relapse, discontinued and partial response. Results: Ninety one of 152 patients 
were treatment naïve, and the 61 were treatment experienced. Relapse was the 
dominating response type (50%). GT1 patient ratio was 65,8%, non GT1 patient was 
5,9%, and 28% of patients were unknown at the date of the report. 42.8% of patients 
were male, the mean age was 55.1 . The physicians have not recommended treat-
ment for 73.6% of patiens, and 16.4% of patients rejected the treatment. The leading 
reasons for physicians and the patients were “waiting for IFN-free treatment option” 
is followed by “presumed tolerabilty issue”. ConClusions: IFN based therapy 
has been the standard of care for CHC infection for many years yet the antiviral 
treatment paradigm of HCV has rapidly evolved since the introduction of IFN-free 
direct acting antivirals. Higher efficacy with less side effects seems to improving 
the standard of care.
GasTroInTesTInal DIsorDers – health care use & Policy studies
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DIaGnosIs anD manaGemenT of moDeraTe-To-seVere IrrITable bowel 
synDrome wITh consTIPaTIon (Ibs-c) In Germany: resulTs from The 
IbIs-c sTuDy
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objeCtives: This is the first study to assess the diagnostic and therapeutic man-
agement of moderate-to-severe IBS-C in six European countries (France, Germany, 
Italy, Spain, Sweden and UK). Here we present the diagnosis and management 
results from Germany. Methods: Observational 12-month study (6 months ret-
rospective and 6 months prospective) in patients diagnosed with IBS-C (Rome-III 
criteria) in the last five years and moderate-to-severe disease severity at inclusion 
(IBS-Symptom Severity Scale (IBS-SSS) score ≥ 175). One of the main objectives was 
to determine healthcare resource utilisation (HRU) and costs prior to and after 
an active phase of the disease. Results: 102 patients were included (43% severe, 
mean age [±SD] 47.6±18.1 years old, 83.3% female). Mean time since diagnosis: 
4.6±8.4 years; mean symptom duration: 15.0±16.9 years. Diagnostic procedures 
since the onset of symptoms were highly variable: the most common were colo-
noscopies(78.4%), blood tests (65.7%), and abdominal ultrasounds(62.7%). The main 
associated comorbidities were insomnia(31.4%), hypertension(28.4%), chronic pain 
(27.5%), depression(27.5%), and gastroesophageal reflux disease (GERD; 27.5%). 
66.7% of patients had an average of 4.0±2.5 diagnostic tests during follow-up and 
71.6% took prescription drugs (54.9% for IBS-C). The most common medication 
groups were laxatives (35.6%), prokinetics (23.3%), antispasmodics (15.1%), and 
analgesics (11.0%). Overall, 69.6% of patients took non-prescription drugs for their 
IBS-C (32.4% laxatives and 19.6% herbal medicine) and 27.5% of patients sought 
complementary therapies. Overall, improvement in symptom severity (IBS-SSS 
total score±SD) was observed between baseline (288.3±78.8) and the 6-month visit 
(228.1±9.1). ConClusions: Patients with moderate-to-severe IBS-C often remain 
undiagnosed for over 10 years and undergo a variety of diagnostic procedures. 
Chronic comorbidities are frequent. Despite a high use of both prescription and 
non-prescription drugs, mean symptom severity did improve but remained “mod-
erate” overall.
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objeCtives: Assess clinical characteristics and patterns of care among patients 
with G1 Hepatitis C virus (HCV) in EU. Methods: A multi-center retrospective 
chart-review study of HCV patients was conducted in the EU (France/Germany/
Italy/Spain/UK) in 4Q2014 to collect de-identified data on diagnosis, clinical 
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healTh-relaTeD QualITy of lIfe, work ProDucTIVITy, anD DaIly 
acTIVITy amonG a samPle of commercIally InsureD PaTIenTs 
wITh IrrITable bowel synDrome wITh consTIPaTIon or chronIc 
consTIPaTIon In The unITeD sTaTes
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objeCtives: To assess the impact of irritable bowel syndrome with constipation 
(IBS-C) and chronic constipation (CC) on health-related quality of life (HRQOL), 
work and daily activity among US commercially-insured patients. Methods: 
Consenting survey-eligible patients ≥ 18 years identified from the HealthCore 
Integrated Research Database completed a cross-sectional survey. IBS-C cases that 
had ≥ 1 IBS claim and either ≥ 2 constipation claims or ≥ 1 constipation claim and 
≥ 1 constipation-related pharmacy claim and CC cases that had ≥ 2 constipation 
claims ≥ 90 days apart or ≥ 1 constipation claim and ≥ 1 constipation-related phar-
macy claim ≥ 90 days apart were included. Controls were matched on age, gender, 
region, plan type and insurance status. Only cases meeting and controls not meeting 
modified Rome III criteria completed the survey. Short Form-12 v2 physical com-
ponent summary (PCS) and mental component summary (MCS) [range: 0–100; US 
normative mean= 50]) and EuroQol-5D (EQ-5D; range: 0= death to 1= perfect health) 
assessed HRQOL. Work Productivity and Activity Impairment Questionnaire (General 
Health version) assessed absenteeism, presenteeism and daily activities (higher 
percentages indicate greater impairment). Indirect costs were calculated based on 
overall work productivity loss (absenteeism+presenteeism) using the human capi-
tal method. Results: Among 354 respondents (177 IBS-C/CC cases, 177 controls; 
mean age 46±15 years; 86% female; 66% employed), mean PCS and MCS scores 
were lower for cases versus controls (mean differences: 8.9 (p< 0.01), 6.8 (p< 0.01), 
respectively). EQ-5D mean utility score was lower among cases versus controls 
(0.7 versus 0.9; p< 0.01). Cases also had greater overall work productivity loss (28% 
versus 12%; p< 0.01) and activity impairment (39% versus 15%; p< 0.01). Estimated 
indirect costs were $108 higher per employed respondent/week for cases versus 
controls (p< 0.01). ConClusions: IBS-C/CC patients reported lower HRQOL and 
greater impairments in work and daily activity compared with matched controls. 
Treatments that effectively manage IBS-C/CC symptoms may improve these out-
comes in IBS-C/CC patients.
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objeCtives: Liver diseases (LDs) can reduce health-related quality-of-life (HRQoL), 
with an important impact on the burden of LDs. Our aim was to analyze the 
impact of the major LDs on EQ-5D Visual Analogue Scale (VAS) and utility-index 
(UI) through different regression models, using HRQoL of the general population 
as a reference. Methods: HRQoL data were measured using the EQ-5D-3L in a 
sample of patients with 9 major LDs enrolled during 2011-2012 in a multicenter 
study conducted in the most populated region of Italy, Lombardy. Such data 
were added to those recorded in 2013 on a representative sample of Lombardy 
general population. Relationships between the outcomes of interest (VAS and UI) 
and LDs were explored through ordinary least squares (OLS) and Tobit regression, 
that accounts for ceiling effect, adjusting for age and gender. Goodness-of-fit was 
assessed through R2 (OLS) and pseudo-R2(Tobit). Results: The sample included 
9,817 subjects (3,017 with LDs). OLS and Tobit regressions performed similarly on 
VAS (R2:0.13,pseudo-R2:0.12) and estimated the largest and significant HRQoL reduc-
tion in patients with decompensated cirrhosis (DC), followed by those with autoim-
mune hepatitis (AIH) and hepatocellular carcinoma (HCC). As for UI, the Tobit model 
performed better than OLS regression (R2:0.11,pseudo-R2:0.15), with the highest 
decrease estimated in patients with DC, followed by those with HCC and compen-
sated cirrhosis. ConClusions: The Tobit model performed slightly better than OLS 
regression on the UI, but not on VAS, maybe due to a stronger ceiling effect in UI. 
This distributional difference mirrors different data-generation mechanisms: UI is 
derived from the EQ-5D-3L domains, while VAS is reported by patients. Therefore, 
VAS and UI might capture different aspects of HRQoL, as supported by our results, 
that show how the same LD can be differently associated with VAS and UI (e.g.: AIH 
seemed to have an impact on VAS only, while HCC on UI only).
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objeCtives: The number of patients over 19 years with registered inflammable 
bowel disease which has non-infectious origin is duplicated in the last 16 years (KSH 
2013). Our aim is to get a picture about the different dimensions of life quality in the 
course of the chronic disease. Methods: Cross-sectional, quantitative examina-
tion was carried out between 15.07.2014 and 31.12.2014 at the Clinical Centre of the 
University of Pécs. Patients with M Crohn and ulcerative colitis between the age of 
18 and 46 were selected with non-randomized, convenience sampling method. For 
data collection we used standard questionnaires (Illness Intrusiveness Rating Scale, 
IBDQ, Coloplast life quality questionnaire) and questions about demographic data 
(N= 103). We used Microsoft Excel 2013 software to carry out descriptive statistics, 
two-sample t-test and χ 2- test (p< 0.05). Results: The age of the patients were 
between 31.03±8.18. Illness Intrusiveness Rating Scale (the effect of the disease 
on role efficiency) was evaluated more unfavourable by the patients with ulcera-
tive colitis (p< 0.05). Average life quality is not affected by gender (p= 0.21), marital 
status (p= 0.15), te type of the disease (p= 0.77), and employment status (p= 0.75). 
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The burDen of moDeraTe-To-seVere IrrITable bowel synDrome wITh 
consTIPaTIon (Ibs-c) In france: a comParIson wITh The euroPean 
resulTs from The IbIs-c obserVaTIonal sTuDy
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objeCtives: To describe the population of moderate-to-severe IBS-C patients in 
French clinical practice and to compare the main data with the European data from 
the IBIS-C study. The IBIS-C study was conducted in six European countries (France, 
Germany, Italy, Spain, Sweden and UK). Methods: Observational, retrospective-
prospective (6 months each) study of patients diagnosed (Rome-III criteria) in the 
last five years and moderate-to-severe IBS-C severity at inclusion (IBS-Symptom 
Severity Scale [IBS-SSS] score ≥ 175). Healthcare resource utilisation (HRU) was ret-
rospectively and prospectively assessed and quality-of-life (QoL) was assessed at 
baseline with IBS-QoL and EuroQoL-5D (EQ-5D). Results: Patient characteristics 
were similar between the French (n= 59) and European (n= 525) cohorts: mean (±SD) 
age 47.7±15.7 and 45.3±15.8 years; 83% and 87% were female, and 63% and 60% had 
severe IBS-C. Mean symptom duration: 13.5±13.5 and 12.8±13.1 years; mean time 
since diagnosis: 2.6±6.3 and 3.0±5.2 years. At baseline, mean IBS-QoL was 42.9±19.0 
and 54.9±22.7 (scale: 0-100[worst-best]); mean EQ-5D was 46.6±22.2 and 55.5±21.7 
(scale: 0-100[worst-best]). Over follow-up, 76% French and 73% European patients 
consulted a GP (mean: 4.2 and 4.9 visits), and 100% and 92% a gastroenterologist 
(mean: 2.2 and 2.8 visits). 17% and 18% required emergency department visits/hos-
pitalisation (mean stay: 6±6 and 14±24 days). 51% and 65% of patients took prescrip-
tion drugs for their IBS-C, 61% and 67% took non-prescription drugs. Mean symptom 
severity (IBS-SSS) improved: 338.9±78.6 (baseline) to 281.5±102.1 (6 months) for the 
French cohort; 323.2±84.3 to 253.9±105.6 for the European cohort. The total mean 
(95%CI) annual cost for moderate-to-severe IBS-C was € 4,128 (2,262-6,633) for 
the French cohort; € 4,639 (3,733-5,598) for the European cohort. ConClusions: 
Moderate-to-severe IBS-C symptoms in France were similar to those other European 
countries. QoL impairment and HRU were high for both cohorts. Moderate-to-severe 
IBS-C continued to be a burden for both cohorts with a high economic cost despite 
availability of therapeutic interventions.
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objeCtives: To understand medical resource utilisation (MRU) of Australian 
patients with genotype 1 chronic hepatitis C (GT1 CHC) including those receiv-
ing current standard of care treatment (telaprevir or boceprevir with pegylated 
interferon and ribavirin). Methods: Medical records were reviewed for a strati-
fied random sample of GT1 CHC patients first attending two liver clinics between 
2011 and 2013 (principal population; PP) supplemented by all GT1 CHC patients 
attending one transplant clinic in the same period (transplant population; TP). 
CHC-related MRU (percentage and annual rate [poisson] of outpatient, hospitali-
sation, laboratory and imaging tests) is reported for the PP by treatment status 
(treated/not treated) stratified by fibrosis grade; and for TP pre-transplant, year 
of transplant and post-transplant. Results: Comprehensive MRU was collected 
for 276 PP patients (F0-1 n= 59, F2 n= 58, F3 n= 53, F4 n= 106; 38 were treatment 
experienced prior to first visit; mean follow-up 17.6 months). Fifty-five (19.9%) 
received triple therapy. Data were collected for 112 TP patients (mean follow-up 
29.9 months), 33 (29.5%) received a transplant during the study and 51 (45.5%) 
beforehand. MRU was higher while treated including annual rates of outpatient 
visits (PP: 9.67 vs 2.91 [F0-1 2.60, F2 2.56, F3 2.63, F4 3.33]; TP: transplant 18.00 vs 
pre 5.55, post 5.14), psychiatric visits (PP: 0.71 vs 0.18 [F0-1 0.25, F2 0.16, F3 0.20, 
F4 0.14]; TP: transplant 0.00 vs pre 0.50, post 0.01), nurse visits (PP: 1.84 vs 0.42 
[F0-1 0.58, F2 0.42, F3 0.51, F4 0.32]); and the percentage with hospitalisation (PP: 
27.3% vs 13.0% [F0-1 3.4%, F2 10.3%, F3 9.4%, F4 21.7%]; TP: transplant 100% vs pre 
96.5%, post 79.2%). ConClusions: CHC-related MRU increases substantially with 
disease severity. To our knowledge, these are the first real-world MRU reported 
for GT1 CHC in Australia and will be valuable in assessing the impact of new 
hepatitis C treatments.
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healTh TechnoloGy assessmenT In chronIc hePaTITIs c: assessmenT 
of DecIsIon lanDscaPe anD manufacTurer InPuTs In sIx aGencIes
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objeCtives: To evaluate the landscape of health technology assessment (HTA) 
decisions for chronic hepatitis C (CHC) therapies in Canada (CADTH), Australia 
(PBAC), England and Wales (NICE), Scotland (SMC), Germany (IQWiG), and France 
(HAS). Methods: Selected HTA agency websites were searched for submissions 
made in the CHC therapy area. Submissions were searched for following informa-
tion: clinical and economic input provided in the submission, recommendations 
from HTA agencies, and drivers of HTA decisions. Results: Victrelis®, Daklinza®, 
Roferon A®, Intron A®, Harvoni®, Viekirax®, Pegasys RBV®, PegIntron®, Rebetol®, 
Olysio®, Sovaldi®, and Incivo® were the pharmacotherapies for which manufac-
turer submissions were available across selected agencies. The number of HTA 
submissions with completion status ranged from 6-12. The percentage recommen-
dation ranged from 43% in Australia to 100% in France and Canada. The number 
of clinical studies supporting the manufacturer submission ranged from 2-12. The 
status, and treatment patterns. Physicians were screened for duration of prac-
tice (≥ 3yrs) and patient volume (≥ 15 HCV patients/mo) and recruited from a 
large panel to be geographically representative. Medical charts of the next 10 
consecutive HCV patients were abstracted. G1 HCV patient data was ana-
lyzed. Results: 2067 eligible G1 HCV patients were included in the analysis 
(France:374/Germany:506/Italy:412/Spain:475/UK:300). Patient characteristics 
included (France/Germany/Italy/Spain/UK) - mean age (yrs):53/49/55/52/45; male: 
61%/67%/61%/59%/69%; patient weight < = 80kg:81%/66%/83%/74%/76%; major-
ity were G1-subtype A (52%/44%/31%/34%/68%) or B (48%/54%/68%/66%/32%); 
any substance-abuse:23%/18%/10%/17%/47%; route of infection via intravenous 
drug use:55%/33%/31%/41%/69%, via blood transfusion:19%/26%/21%/36%/7%, 
via heterosexual contact:5%/11%/22%/11%/7%, via homosexual con-
tact:8%/13%/10%/6%/12%; current fibrosis scores were – F0:9%/18%/6%/7%/20%, 
F1:18%/30%/25%/25%/32%, F2:24%/28%/32%/24%/18%, F3:21%/17%/17%/20%/11%, 
F4:29%/6%/20%/23%/19%. In France/Germany/Italy/Spain/UK, latest mean alanine 
aminotransferase levels were:58/90/95/62/73; patients with undetectable (0-500) 
viral load (VL):5%/2%/25%/2%/1%; 501-< = 1Million VL-count:58%/39%/52%/75%; > 1M 
VL-count:38%/26%/38%/45%/25%. Treatment patterns included (France/Germany/
Italy/Spain/UK)- currently treated:23%/28%/20%/17%/20%, not currently treated 
(previous treatment non-responder, discontinued or relapsed, or therapy com-
plete and awaiting sustained viral response):21%/20%/29%/30%/22%, not current 
treated because patient achieved sustained viral response:19%/12%/11%/13%/6%; 
treatment naïve/never been treated:38%/40%/41%/41%/52%. ConClusions: 
In this cohort of G1 HCV patients, treatment rates and disease burden varied 
among studied countries in EU; only a small proportion of patients had unde-
tectable VL or was not treated owing to achieving sustained viral response. 
Further research is warranted to assess the observed treatment patterns, effec-
tiveness of regimens, and patient management strategies to alleviate patient 
burden.
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objeCtives: The analysis aimed to evaluate the evolution of the national and 
regional public expenditure regarding Proton Pump Inhibitors (PPIs) in Italy, in 
relation to national and regional policies. Methods: The analysis combined 
data published by the Italian Medicines Agency (AIFA) and Regions and regional 
and national laws, to understand the impact of the applied policies on PPIs 
expenditure. Results: Over the past ten years, PPIs consumption increased 
by 280% (around 14% yearly), with lansoprazole reaching +533%. The number 
of patients ≥ 18 treatable with PPIs in 2013 was 2.873.500 (6% of adult popu-
lation), being the first class in terms of expenditure with a per capita value of 
15.2€ and consumptions of 74 DDD/1.000 inh./die. Consumptions and expenditure 
incresed by respectively 6.5% and 1.6% vs 2012. AIFA also highlighted a trend to 
prescriptive inappropiateness over the years, where the 46.5% of patients do not 
meet the reimbursability criteria by law. At regional level, Regions have issued 
a number of regional laws to contain both consumptions and expenditure (e.g. 
through reference pricing or guidelines to encourage the prescription of generi-
cated drugs), identifying specific performance indicators and target values. We 
estimated potential savings from the correct application of the reimburability 
criteria amounting to 260 million € /year, if Regions were able to control pre-
scriptive appropriateness, to which additional savings could be added through 
focused cost-containment measures. ConClusions: Despite a number of 
efforts at both central and regional level, the trend towards inappropriateness 
and expenditure increase of PPIs is confirmed. A review of both national and 
regional policies on PPIs expenditure is key to reduce the current waste of eco-
nomic resources and, with a stable total budget, guarantee additional funding for 
innovation.
PGI55
assessInG The raTIonalITy of cosTs of DruG TreaTmenT of 
nonalcoholIc sTeaTohePaTITIs In The hosPITal of ukraIne
Iakovlieva L, Tkachova O, Mishchenko O, Gerasymova O, Zavadska I, Lyashenko N
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: Comprehensive assessment of the financial costs of drug treatment of 
nonalcoholic steatohepatitis (NASH) in a hospital of Kharkiv, Ukraine. Methods: 
For the study, the schemes medicinal histories of 54 patients with NASH in a hos-
pital in Kharkov during 2013 were used. The structure of costs of NASH treatment 
was assessed by the ABC analysis. Assessment of the level of NASH treatment cor-
respondence was conducted by the formal VEN analysis according to the National 
Drug Formulary (NDF) of Ukraine (2013). Index “V” was put in case of availability of 
the drug in the NDF, index “N” – in case of its absence. Directions of NASH treat-
ment were assessed by the prescriptions of drugs according to requirements of 
Ukrainian Cinical Guidelines (O.Ia. Babak, 2007) and according to Practice Guideline 
by the American Association for the Study of Liver Diseases (AASLD) for 2012. In 
determining the cost of drugs, their prices as of May 2015 by the data of Morion 
reference and retrieval system “Drugs” were used. Results: Drug treatment of 
patients with NASH by pharmacotherapeutic groups met the basic requirements 
of Ukrainian Clinical Guidelines and Guidelines of American scientists AASLD, 
which confirms the rationality of prescriptions. According to the ABC/VEN analy-
sis, most of the funds for treatment (82%) were spent on 76% of drugs included in 
the NDF. But 24% of drugs were missing from the NDF of Ukraine, indicating the 
need to correct NASH treatment in the hospital of Ukraine. ConClusions: 76% 
of drugs prescribed to patients with NASH can be considered rational, but 24% of 
drugs had index “N”, indicating their inappropriate use. Comparison of the ABC 
and VEN analysis showed the need to correct NASH treatment in the hospital of 
Ukraine, as 18% of funds were spent on minor drugs which are not represented 
the NDF of Ukraine.
